Shares of biotech company Inovio Pharmaceuticals INO fell sharply on Tuesday after announcing updates to its candidate vaccine Covid-19, INO-4800. INO fell 20% during the day before getting a little closer again.
Inovio said his early-stage clinical study showed positive results and that the vaccine was considered safe and well tolerated; 94% of the 40 participants “demonstrated general immune responses”.
However, investors expected more specific information on the vaccine’s effectiveness, and Inovio did not provide any information on how many patients produced antibodies. Antibodies are key: they prevent infection with the coronavirus.
Inovio expects to start a phase 2/3 clinical study this summer after obtaining FDA approval.
Be among the first investors in the new type of device that experts say could affect society as much as the discovery of electricity. Current technology will soon be outdated and will be replaced by these new devices. In the process, it is expected to generate 22 million jobs and generate $ 12.3 trillion of activity.
A few select actions could be triggered further as implementation accelerates for this new technology. Early investors might see gains similar to Microsoft’s purchase in the 1990s. Zacks’ recently released special report reveals 8 stocks to watch. The report is only available for a limited time.
Related
